

Oncolytic Virus Therapies Market Expected to Experience Major Growth by 2034, According to DelveInsight

DelveInsight's Oncolytic Virus Therapies Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NV, UNITED STATES,
February 12, 2025 /EINPresswire.com/
-- DelveInsight's "Oncolytic Virus Therapies Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Oncolytic Virus Therapies, historical and forecasted epidemiology as well as the Oncolytic Virus Therapies market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



The Oncolytic Virus Therapies market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Oncolytic Virus Therapies pipeline products will significantly revolutionize the Oncolytic Virus Therapies market dynamics.

To Know in detail about the Oncolytic Virus Therapies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Oncolytic Virus Therapies Market Forecast](#)

Some of the key facts of the Oncolytic Virus Therapies Market Report:

- The Oncolytic Virus Therapies market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- In January 2025, Novotech, a leading global full-service clinical Contract Research Organization (CRO) collaborating with biotech and small to mid-sized pharmaceutical companies to fast-track the development of innovative therapeutics, has published its latest report, Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This in-depth whitepaper examines the shifting

landscape of oncolytic virus therapies (OVT), offering valuable insights into this groundbreaking cancer treatment approach.

- In July 2024, KaliVir Immunotherapeutics, Inc., a biotech company focused on developing innovative, multi-mechanistic oncolytic viral immunotherapy programs, announced today that the FDA has approved the Investigational New Drug (IND) application for the STEALTH-001 study of VET3-TGI in patients with advanced, incurable solid tumors.
- In March 2024, Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is excited to announce that its Phase 1 clinical trial of the CD19 oncolytic virotherapy drug candidate onCARlytics (on-CAR-19, CF33-CD19 HOV4) has successfully completed its first cohort in the intratumoral monotherapy arm. As a result, the trial is now ready to begin combination dosing with the CD19-targeting drug blinatumomab (Blinicyto[®], marketed by Amgen) for patients with solid tumors.
- The United States holds the largest market share in oncolytic virus therapies, representing over 70% of the total market, surpassing EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
- In November 2023, Genelux revealed that the US FDA has awarded Fast Track designation (FTD) for the developmental initiative of Olvi-Vec (olvimulogene nanivacirepvec) aimed at treating individuals with platinum-resistant/refractory ovarian cancer.
- DelveInsight's analysis indicates that prostate cancer constituted approximately 20% of the overall target patient population for oncolytic virus therapies in the 7MM in 2023.
- In 2023, melanoma comprised around 10% of the total new cases among selected cancers in the 7MM.
- The oncolytic virus pipeline is robust, with leading pharmaceutical firms like Replimune, Genelux, Imugene, EpicentRx, and others actively involved in advancing research to improve cancer treatment choices.
- As per GLOBOCAN, the anticipated number of new cases of breast cancer in the United States is projected to increase from 274,375 in 2022 to 321,295 by 2035.
- At present, there are only two approved oncolytic virus therapies: IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen), authorized in the US, Europe, and Japan since 2015, and DELYTACT (teserpaturev/G47Δ; Daiichi Sankyo), sanctioned in Japan in 2021.
- Key Oncolytic Virus Therapies Companies: Amgen, Daiichio Sankyo, Genelux, Replimune, Binhui Biopharmaceutical, Zhejiang Cancer Hospital, and others
- Key Oncolytic Virus Therapies Therapies: IMLYGIC (T-VEC), DELYTACT (G47Δ), Olvi-Vec, RP1, OH2 injection, H101, Camrelizumab, and others

- The Oncolytic Virus Therapies market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Oncolytic Virus Therapies pipeline products will significantly revolutionize the Oncolytic Virus Therapies market dynamics.

Oncolytic Virus Therapies Overview

Oncolytic virus therapy is a promising approach to cancer treatment that utilizes viruses to selectively target and destroy cancer cells while sparing healthy cells. These viruses are engineered or modified to infect and replicate within cancer cells, leading to their destruction through various mechanisms, including direct cell lysis, induction of anti-tumor immune responses, and inhibition of tumor blood supply.

Get a Free sample for the Oncolytic Virus Therapies Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Oncolytic Virus Therapies Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Oncolytic Virus Therapies Epidemiology Segmentation:

The Oncolytic Virus Therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

- Total Prevalence of Oncolytic Virus Therapies
- Prevalent Cases of Oncolytic Virus Therapies by severity
- Gender-specific Prevalence of Oncolytic Virus Therapies
- Diagnosed Cases of Episodic and Chronic Oncolytic Virus Therapies

Download the report to understand which factors are driving Oncolytic Virus Therapies epidemiology trends @ [Oncolytic Virus Therapies Epidemiology Forecast](#)

Oncolytic Virus Therapies Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Oncolytic Virus Therapies market or expected to get launched during the study period. The analysis covers Oncolytic Virus Therapies market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Oncolytic Virus Therapies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Oncolytic Virus Therapies Therapies and Key Companies

- IMLYGIC (T-VEC): Amgen
- DELYTACT (G47Δ): Daiichio Sankyo
- Olvi-Vec: Genelux
- RP1: Replimune
- OH2 injection: Binhui Biopharmaceutical
- H101, Camrelizumab: Zhejiang Cancer Hospital

Oncolytic Virus Therapies Market Drivers

- Increasing prevalence of cancer worldwide, driving the demand for novel treatment options.
- Advancements in biotechnology and genetic engineering, facilitating the development of more effective oncolytic viruses.
- Growing investment in research and development by pharmaceutical companies and government agencies.
- Potential for combination therapies with other cancer treatments, enhancing efficacy and patient outcomes.
- Rising awareness among healthcare professionals and patients about the benefits of oncolytic virus therapies.

Oncolytic Virus Therapies Market Barriers

- Limited understanding of the mechanisms of action and long-term safety profiles of oncolytic viruses.
- Challenges in manufacturing and scalability of oncolytic virus production.
- High costs associated with research, development, and clinical trials.
- Regulatory hurdles and approval processes for new oncolytic virus therapies.
- Patient selection and stratification challenges, including variability in treatment responses among different cancer types and patients.

Scope of the Oncolytic Virus Therapies Market Report

- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Oncolytic Virus Therapies Companies: Amgen, Daiichio Sankyo, Genelux, Replimune, Binhui Biopharmaceutical, Zhejiang Cancer Hospital, and others

- Key Oncolytic Virus Therapies Therapies: IMLYGIC (T-VEC), DELYTACT (G47Δ), Olvi-Vec, RP1, OH2 injection, H101, Camrelizumab, and others
- Oncolytic Virus Therapies Therapeutic Assessment: Oncolytic Virus Therapies current marketed and Oncolytic Virus Therapies emerging therapies
- Oncolytic Virus Therapies Market Dynamics: Oncolytic Virus Therapies market drivers and Oncolytic Virus Therapies market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Oncolytic Virus Therapies Unmet Needs, KOL's views, Analyst's views, Oncolytic Virus Therapies Market Access and Reimbursement

To know more about Oncolytic Virus Therapies companies working in the treatment market, visit @ [Oncolytic Virus Therapies Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Oncolytic Virus Therapies Market Report Introduction
2. Executive Summary for Oncolytic Virus Therapies
3. SWOT analysis of Oncolytic Virus Therapies
4. Oncolytic Virus Therapies Patient Share (%) Overview at a Glance
5. Oncolytic Virus Therapies Market Overview at a Glance
6. Oncolytic Virus Therapies Disease Background and Overview
7. Oncolytic Virus Therapies Epidemiology and Patient Population
8. Country-Specific Patient Population of Oncolytic Virus Therapies
9. Oncolytic Virus Therapies Current Treatment and Medical Practices
10. Oncolytic Virus Therapies Unmet Needs
11. Oncolytic Virus Therapies Emerging Therapies
12. Oncolytic Virus Therapies Market Outlook
13. Country-Wise Oncolytic Virus Therapies Market Analysis (2020–2034)
14. Oncolytic Virus Therapies Market Access and Reimbursement of Therapies
15. Oncolytic Virus Therapies Market Drivers
16. Oncolytic Virus Therapies Market Barriers
17. Oncolytic Virus Therapies Appendix
18. Oncolytic Virus Therapies Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/785458419>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.